The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK.
The call comes as an ICR survey found that as many as 16% of patients had either been denied a drug recommended by their doctors or experienced delays in receiving a recommended treatment.
Meanwhile, nearly half of those surveyed who had tried to enrol in clinical trials had been unable to do so.
The ICR have thus called on government and the pharmaceutical industry to increase speed of access to cancer drugs in the UK.
Original Article: ICR calls for faster access to innovative cancer drugs